Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s):  BIOAF

Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.


TSXV:BTI.H - Post by User

Comment by Boomskidon May 04, 2023 10:05am
64 Views
Post# 35429768

RE:RE:Non-human primate testing

RE:RE:Non-human primate testingCan you explain to us, poof, how RNAi might compete with the transport of existing therapies like Herceptin (xB3-001), IL-1Ra (xB3-004), and other biologics across the BBB?

You have an irresponsible habit of posting with no analysis or context. For years it's been left to me and others to clean up the messes you've created.

Tell us the scope of possibilities with RNAi, how it might medically compete with RMT (xB3 and Denali's TV), what the manufacturing scenarios look like compared to RMT fusion proteins, etc, etc.

Time to belly up to the bar, poof. I suggest that you can't do it unless somebody else gives you the answers.

Note: The performance of biotech indexes and related share prices are irrelevant to these questions.

jd
<< Previous
Bullboard Posts
Next >>